To analyze if clinically insignificant prostate cancer （CIPC） is more frequently detected with repeat prostate biopsies, we retrospectively analyzed the records of 2146 men diagnosed with prostate cancer after one o...To analyze if clinically insignificant prostate cancer （CIPC） is more frequently detected with repeat prostate biopsies, we retrospectively analyzed the records of 2146 men diagnosed with prostate cancer after one or more prostate biopsies. The patients were divided into five groups according to the number of prostate biopsies obtained, e.g, group I had one biopsy, group 2 had two biopsies and group 3 had three biopsies. Of the 2146 patients diagnosed with prostate cancer, 1956 （91,1%）, 142 （6.6%）, 38 （1.8%）, 9 （0.4%） and 1 （0.1%） men were in groups 1, 2, 3, 4 and 5, respectively. Groups 4 and 5 were excluded because of the small sample sizes. The remaining three groups （groups 1, 2 and 3） were statistically analyzed. There were no differences in age or prostate-specific antigen level among the three groups. CIPC was detected in 201 （10.3%）, 28 （19.7%） and 9 （23.7%） patients in groups 1, 2 and 3, respectively （P〈O.O01）. A multivariate analysis showed that the number of biopsies was an independent predictor to detect ClPC （0R=2.688 for group 2; 0R=4.723 for group 3）. In conclusion, patients undergoing multiple prostate biopsies are more likely to be diagnosed with CIPC than those who only undergo one biopsy. However, the risk still exists that the patient could have clinically significant prostate cancer. Therefore, when counseling patients with regard to serial repeat biopsies, the possibility of prostate cancer overdiagnosis and overtreatment must be balanced with the continued risk of clinically significant disease.展开更多
文摘To analyze if clinically insignificant prostate cancer （CIPC） is more frequently detected with repeat prostate biopsies, we retrospectively analyzed the records of 2146 men diagnosed with prostate cancer after one or more prostate biopsies. The patients were divided into five groups according to the number of prostate biopsies obtained, e.g, group I had one biopsy, group 2 had two biopsies and group 3 had three biopsies. Of the 2146 patients diagnosed with prostate cancer, 1956 （91,1%）, 142 （6.6%）, 38 （1.8%）, 9 （0.4%） and 1 （0.1%） men were in groups 1, 2, 3, 4 and 5, respectively. Groups 4 and 5 were excluded because of the small sample sizes. The remaining three groups （groups 1, 2 and 3） were statistically analyzed. There were no differences in age or prostate-specific antigen level among the three groups. CIPC was detected in 201 （10.3%）, 28 （19.7%） and 9 （23.7%） patients in groups 1, 2 and 3, respectively （P〈O.O01）. A multivariate analysis showed that the number of biopsies was an independent predictor to detect ClPC （0R=2.688 for group 2; 0R=4.723 for group 3）. In conclusion, patients undergoing multiple prostate biopsies are more likely to be diagnosed with CIPC than those who only undergo one biopsy. However, the risk still exists that the patient could have clinically significant prostate cancer. Therefore, when counseling patients with regard to serial repeat biopsies, the possibility of prostate cancer overdiagnosis and overtreatment must be balanced with the continued risk of clinically significant disease.
